Posted Two Blokes
byFirst results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu
Source: Two Blokes Trading
Posted Two Blokes
byLargest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted
Source: Two Blokes Trading
Posted Two Blokes
byNEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical com
Source: Two Blokes Trading
Posted Two Blokes
byBeijing has been canvassing companies and waiving duties on American goods in sectors where it lacks alternati
Source: Two Blokes Trading
Posted Two Blokes
byCG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohor
Source: Two Blokes Trading
Posted Two Blokes
byAstellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Particip
Source: Two Blokes Trading
Posted Two Blokes
byHeritage Foundation senior visiting fellow and economist Stephen Moore speaks with Fox News Digital about how
Source: Two Blokes Trading
Posted Two Blokes
byNEW YORK , April 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purc
Source: Two Blokes Trading
Posted Two Blokes
byNEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds p
Source: Two Blokes Trading
Posted Two Blokes
byNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST tria
Source: Two Blokes Trading
Posted Two Blokes
byPhase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than
Source: Two Blokes Trading
Posted Two Blokes
byPhase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than
Source: Two Blokes Trading